Mark Eisner, M.D., M.P.H., currently serves as the Executive Vice President and Chief Medical Officer at VIR Biotechnology Inc., a position that underscores his extensive expertise in the fields of medicine and public health. Dr. Eisner earned his medical degree from the University of California, San Francisco, and later obtained a Master of Public Health from the same institution. His career has been marked by a deep commitment to advancing medical research and improving patient outcomes, particularly in the realm of infectious diseases. Before joining VIR Biotechnology, Dr. Eisner held significant roles that honed his skills in clinical development and medical affairs. He worked at Genentech, where he was instrumental in leading clinical development programs for respiratory and infectious diseases. His tenure at Genentech was characterized by his ability to drive innovative research and bring new treatments to market. At VIR Biotechnology, Dr. Eisner leverages his vast experience to oversee the company's clinical development strategy, ensuring that the organization remains at the forefront of developing groundbreaking therapies for infectious diseases. His leadership is pivotal in steering VIR's efforts to combat global health challenges, including the ongoing fight against COVID-19 and other viral infections. In addition to his corporate roles, Dr. Eisner is an accomplished researcher with numerous publications in peer-reviewed journals. His work has contributed significantly to the understanding of respiratory and infectious diseases, earning him recognition within the scientific community. As the Chief Medical Officer at VIR Biotechnology, Dr. Eisner continues to play a crucial role in shaping the company's mission to address some of the most pressing health issues of our time, demonstrating his unwavering dedication to improving global health outcomes.